Aid in diagnosis of leucine-rich glioma inactivated 1 protein (LGI1) antibody disorders associated with limbic encephalitis, hyponatremia, and myoclonic movements. Disorders are rarely associated with tumors. Use to manage antibody-positive (LGI1) individual following immunotherapy and/or plasmapheresis.
- Patient Preparation
- Serum separator tube.
- Specimen Preparation
- Separate serum from cells within 2 hours of collection. Transfer 1 mL serum to an ARUP Standard Transport Tube. (Min: 0.2 mL)
- Storage/Transport Temperature
- Unacceptable Conditions
- CSF or plasma. Contaminated, hemolyzed, or severely lipemic specimens.
- After separation from cells: Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 year (avoid repeated freeze/thaw cycles)
The presence of LGI1 IgG antibody is mainly associated with limbic encephalitis, hyponatremia and myoclonic movements. LGI1 IgG antibody is rarely associated with tumors but may occur infrequently in Morvan syndrome, neuromyotonia and idiopathic epilepsy. The full-spectrum of clinical disorders associated with the LGI1 IgG antibody continues to be defined. Results should be interpreted in correlation with the patient's clinical history and other laboratory findings.
This indirect fluorescent antibody assay utilizes leucine-rich, glioma-inactivated 1 protein (LGI1) transfected cell lines for the detection and semi-quantification of the LGI1 IgG antibody.
|Component Test Code*||Component Chart Name||LOINC|
|2009457||LGI1 Ab IgG Screen by IFA|